A carregar...
The Future of Combination Therapies of Insulin with a Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes – Is it Advantageous?
Safe and effective therapies for type 2 diabetes are needed to reduce the burden of late complications and costs associated with this chronic disease. Hypoglycaemia and body weight gain are side effects and limitations of the therapy with insulin and/or sulphonylureas. Recently, the combination of g...
Na minha lista:
| Publicado no: | Eur Endocrinol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Touch Medical Media
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5983089/ https://ncbi.nlm.nih.gov/pubmed/29872471 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2014.10.02.98 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|